What obesity therapy did Pfizer acquire rights to in China?

Pfizer acquired the rights to commercialize ecnoglutide, a drug developed by Hangzhou Sciwind Bioscience Co., which is already approved for diabetes and under review for obesity in China.

What is the total value of Pfizer's deal with Sciwind Bioscience?

The deal with Sciwind Bioscience is worth as much as $495 million, including upfront payments and milestone-based fees.

How does Sciwind's ecnoglutide work for weight loss?

Ecnoglutide mimics the natural hormone GLP-1, regulating blood sugar and appetite, and has shown weight loss comparable to Eli Lilly's Zepbound in late-stage studies.

Home / Business and Economy / Pfizer Bets Big on China's Obesity Market

Pfizer Bets Big on China's Obesity Market

24 Feb

•

Summary

Pfizer acquired rights to an obesity therapy in China.
The deal with Sciwind is worth up to $495 million.
The drug mimics GLP-1 and aims for safer efficacy.
Obesity affects 14.1% of Chinese adults.

Pfizer Bets Big on China's Obesity Market

Pfizer Inc. has secured exclusive rights to commercialize an obesity therapy in China, signaling an intensified effort in the rapidly expanding weight loss market. The agreement is with the Chinese startup Hangzhou Sciwind Bioscience Co. for their drug ecnoglutide.

This therapy, recently approved in China for diabetes, is currently under review for obesity treatment. The deal carries a potential value of up to $495 million, comprising an upfront payment and milestone-based fees. Pfizer aims to meet the growing demand in China, where obesity impacts 14.1% of the adult population and is a priority under the government's Healthy China initiative.